Ibrutinib racemate is primarily used in the development and research of treatments for various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It functions as a potent inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B-cells. By blocking BTK, it disrupts the signaling that promotes cancer cell growth and survival, leading to the induction of apoptosis in these cells. This makes it a valuable compound in preclinical studies and drug development aimed at creating effective therapies for B-cell-related cancers. Additionally, its racemic form is often studied to understand the pharmacokinetics, efficacy, and safety profiles of its enantiomers, which can guide the optimization of therapeutic formulations.